For those of you who may be interested, I have posted an update to my
series of articles on the Avastin vs. Lucentis controversy on my web
site. The subject is a commentary about the June 5th WSJ article
wherein Genentech's CEO tried to justify the price differential
between the two drugs for use in treating age-related macular
degeneration. The commentary is written by an attorney involved in the
biotech area.

The update link is: http://irvaronsjournal.blogspot.com/2007/06/avastinlucentis-update-14-genentech-
ceo.html

Irv Arons